Monoclonal Antibodies Consent 🧬
Consent guide for monoclonal antibody treatment: explanation, common risks, alternatives, monitoring, and drug-specific counselling points.
📌 Procedure
- Monoclonal antibody treatment (intravenous infusion or subcutaneous injection).
🧾 Why this is offered
- Monoclonal antibodies are targeted treatments used in cancer, autoimmune, inflammatory, and allergy conditions.
- Choice of agent depends on diagnosis, prior treatment response, and safety profile.
🔍 What to explain during consent
- How treatment is given (day unit infusion or injection schedule).
- Expected benefits and realistic goals of therapy.
- Monitoring plan: blood tests, infection screening, and review appointments.
- Need to report red-flag symptoms early (fever, breathlessness, chest pain, severe rash, reduced urine output).
⚠️ General risks and complications
- Infusion/injection reactions: flushing, rash, dyspnoea, hypotension, fever, and chills (often highest risk during early doses).
- Serious infections can occur, including TB, bacterial sepsis, and opportunistic fungal/viral infections depending on agent.
- Viral reactivation risk (especially hepatitis B with B-cell depleting therapies).
- Organ-specific toxicity depending on agent (cardiac, pulmonary, hepatic, endocrine, neurological, renal, and GI).
- Allergic/anaphylactic reactions (rare but potentially life-threatening; can occur even after prior tolerated doses).
- Potential fetal risk: contraception and pregnancy counselling may be required for selected agents.
🧪 Pre-treatment safety checks
- Baseline bloods as relevant to agent: FBC, renal profile, liver profile, CRP/ESR, and lipids where indicated.
- Infection screening before selected agents: TB and hepatitis B/C (plus HIV where locally indicated).
- Baseline cardiac assessment (e.g. echocardiography) for HER2-targeted therapy such as trastuzumab.
- Review vaccination status and avoid live vaccines during/after treatment windows where contraindicated.
- Document current infection symptoms and defer treatment if clinically unsafe.
💊 Commonly used monoclonal antibodies: key counselling points
- Rituximab: important risks include severe infusion reactions, hepatitis B reactivation, and rare PML; monitor for delayed cytopenias/infection.
- Infliximab / Adalimumab (TNF inhibitors): serious infection risk (TB, fungal, sepsis), possible hepatitis reactivation, caution in demyelination and heart failure.
- Trastuzumab: risk of cardiomyopathy/LVEF reduction; baseline and interval cardiac monitoring are essential.
- Pembrolizumab / Nivolumab: immune-related toxicity can involve lungs (pneumonitis), bowel (colitis), liver (hepatitis), kidneys (nephritis), endocrine organs, skin, and rarely heart/neurological systems.
- Tocilizumab: serious infection risk, transaminitis/hepatotoxicity, neutropenia/thrombocytopenia, lipid elevation, and rare GI perforation.
- Omalizumab: anaphylaxis warning; early-dose post-injection observation and clear emergency advice are required.
🔁 Alternatives
- Standard non-biologic therapy (where appropriate).
- Alternative biologic or targeted therapy classes.
- Supportive care / symptom control alone if treatment not desired or unsuitable.
- No treatment (with discussion of likely disease course and risks).
❓ Common patient questions
- How long will I need this? - Duration depends on indication and response.
- Will I lose my hair? - Usually less common than with traditional chemotherapy, but adverse effects vary by drug.
- Can I get vaccines? - Some live vaccines may be unsuitable; discuss vaccine timing with your specialist team.
- What if I feel unwell after treatment? - Seek urgent medical advice for fever, breathing problems, chest pain, severe diarrhoea, jaundice, confusion, reduced urine output, or severe rash.
📋 Documentation checklist
- Confirm indication, treatment intent, and proposed agent.
- Document material risks, benefits, alternatives, and patient questions.
- Record infection screening status and baseline safety tests where relevant.
- Ensure patient understands follow-up and emergency safety-net advice.
Educational reference only. Medical disclaimer